Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azd2962
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AZD2962 is an oral, small molecule inhibitor of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4). It is being developed as a targeted therapy for hematologic neoplasms, specifically for myelodysplastic syndromes (MDS) and dysplastic chronic myelomonocytic leukemia (CMML). The drug is designed to block IRAK4, a key signaling kinase involved in inflammation and malignant progression in hematologic malignancies. AZD2962 is currently being evaluated in early-phase clinical trials to determine its safety, tolerability, pharmacokinetics, and preliminary efficacy, both as monotherapy and in combination with other agents[1][5][9].
02
Targets
IRAK4 (Interleukin-1 receptor associated kinase 4)
Beyond the preview
Go deeper on azd2962.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azd2962.